Another research paper verifying another mechanism of action, of Leronlimab's control of the tumor microenvironment. This paper is a short read. Scientists show that the tumor(s) reprogram neutrophils via CCL3, and these reprogrammed neutrophils recruit this chemokyne, to the tumor, to assist rapid tumor growth. They have identified blocking CCL3 as a strong therapeutic target.
Leronlimab downregulates CCL3 via of CCR5 blockade.
"Forecasting whether a tumor will stay contained or accelerate is still one of oncology’s biggest unknowns. A team at the University of Geneva (UNIGE) and the Ludwig Institute for Cancer Research reports that one of the immune system’s most common cell types, the neutrophil, can be flipped into a tumor helper after it enters the tumor’s surrounding environment. The study, published in Cancer Cell, points to a single chemical signal, CCL3, as a key feature of that switch and a possible clue to how a cancer is likely to behave."
Immune Cells Meant To Fight Cancer Are Secretly Helping Tumors Grow https://share.google/RvZXm8ZTYyrjkRwYm
Leronlimab downregulates CCL3 via of CCR5 blockade.
"Forecasting whether a tumor will stay contained or accelerate is still one of oncology’s biggest unknowns. A team at the University of Geneva (UNIGE) and the Ludwig Institute for Cancer Research reports that one of the immune system’s most common cell types, the neutrophil, can be flipped into a tumor helper after it enters the tumor’s surrounding environment. The study, published in Cancer Cell, points to a single chemical signal, CCL3, as a key feature of that switch and a possible clue to how a cancer is likely to behave."
Immune Cells Meant To Fight Cancer Are Secretly Helping Tumors Grow https://share.google/RvZXm8ZTYyrjkRwYm
13
